department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Tarpeyo · pharmadog

pharmadog
drugs
Tarpeyo

drug

patient view →

budesonide DR

Marketedupdated 2mo ago

by Calliditas Therapeutics AB

Approved

community read0 votes

all catalysts(4)

approval · 4

BUDESONIDE — FDA approval

BUDESONIDE — FDA approval

BUDESONIDE — FDA approval

BUDESONIDE — FDA approval

News(0)

no news has mentioned this drug yet

brand

Tarpeyo

generic

budesonide

indication

IgA Nephropathy (Berger's Disease)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 9, 2026

125 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (35)

Jan 23, 2043method-of-use (U-3810)US 11896719
Jan 23, 2043method-of-use (U-4086)US 12171882
Jan 23, 2043formulationUS 12171883
Jan 23, 2043formulationUS 12311057
Jan 10, 2039formulationUS 11260064
Jan 10, 2039method-of-use (U-3820)US 11564934
Oct 5, 2038formulationUS 11331442
Oct 5, 2038formulationUS 11833292
Sep 9, 2036method-of-use (U-2554)US 10172802
Sep 9, 2036method-of-use (U-2554)US 10172802
Sep 9, 2036formulationUS 9707182
Sep 9, 2036formulationUS 9707182
Sep 7, 2031formulationUS 10307375
Sep 7, 2031formulationUS 10660858
Sep 7, 2031formulationUS 8895064
Sep 7, 2031formulationUS 9132093
Sep 7, 2031formulationUS 9192581
Mar 17, 2031method-of-use (U-2889)US 88152584.7y
May 28, 2030formulationUS 107167533.9y
May 28, 2030method-of-use (U-2889)US 83242663.9y
May 28, 2030method-of-use (U-2889)US 87038063.9y
May 28, 2030formulationUS 88087133.9y
May 28, 2030method-of-use (U-2889)US 94150093.9y
May 28, 2030formulationUS 94631613.9y
Aug 3, 2029method-of-use (U-3820)US 83241923.1y
Aug 1, 2029formulationUS 90503683.1y
May 7, 2029formulationUS 84919322.8y
Nov 22, 2028formulationUS 102930522.4y
Nov 12, 2028method-of-use (U-3820)US 113578592.4y
Nov 9, 2026formulationUS 11197822125d
Nov 9, 2026formulationUS 11413296125d
Nov 9, 2026method-of-use (U-3820)US 8497258125d
Nov 9, 2026formulationUS 8679545125d
Nov 9, 2026method-of-use (U-3820)US 8975243125d
Nov 9, 2026method-of-use (U-3820)US 9119863125d

FDA exclusivities (4)

Feb 9, 2031ODE-466Orphan Drug (7y)4.6y
Dec 20, 2030ODE-464Orphan Drug (7y)4.5y
Dec 15, 2028ODE-389Orphan Drug (7y)2.4y
Feb 9, 2027NPNP217d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval8 co-mentions · 4 sources
drugbudesonide ER6 co-mentions · 6 sources
drugBUDESONIDE6 co-mentions · 6 sources
drugPulmicort6 co-mentions · 6 sources
drugPulmicort Turbohaler6 co-mentions · 6 sources
tagSmall Molecule4 co-mentions · 4 sources
tagRecall2 co-mentions · 2 sources
companyAstraZeneca Pharmaceuticals LP1 co-mentions · 1 sources

Trials studying budesonide DR

phase2Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthmarecruitingn=1,147
phase3A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthmarecruitingn=200
phase3A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthmarecruitingn=790
phase1A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthmarecruitingn=12
—Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Settingrecruitingn=2,000
phase4A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflationrecruitingn=56
phase4Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Careactive not recruitingn=1,511
—Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greececompletedn=212

more trials →